Male

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: The hypothesis of the study is that treatment with hydroxychloroquine sulphate in hospitalised patients with coronavirus …
Magnus Nakrem Lyngbakken, Jan-Erik Berdal, Arne Eskesen, Dag Kvale, Inge Christoffer Olsen, Anbjørg Rangberg, Christine Monceyron Jonassen, Torbjørn Omland, Helge Røsjø, Olav Dalgard
Cite DOI
Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
BACKGROUND: Skin emollients applied during early infancy could prevent atopic dermatitis, and early complementary food introduction …
Håvard Ove Skjerven, Eva Maria Rehbinder, Riyas Vettukattil, Marissa LeBlanc, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Linn Landrø, Benjamin J. Marsland, Knut Rudi, Kathrine Dønvold Sjøborg, Cilla Söderhäll, Anne Cathrine Staff, Kai-Håkon Carlsen, Anna Asarnoj, Karen Eline Stensby Bains, Oda C. Lødrup Carlsen, Kim M. Advocaat Endre, Peder Annæus Granlund, Johanne Uthus Hermansen, Hrefna Katrín Gudmundsdóttir, Katarina Hilde, Geir Håland, Ina Kreyberg, Inge Christoffer Olsen, Caroline-Aleksi Olsson Mägi, Live Solveig Nordhagen, Carina Madelen Saunders, Ingebjørg Skrindo, Sandra G. Tedner, Magdalena R. Værnesbranden, Johanna Wiik, Christine Monceyron Jonassen, Björn Nordlund, Karin C. Lødrup Carlsen
Cite DOI
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
BACKGROUND: Infliximab (INX) and other tumour necrosis factor inhibitors (TNFi) have revolutionised the treatment of several immune …
Silje W. Syversen, Guro L. Goll, Kristin K. Jørgensen, Inge C. Olsen, Øystein Sandanger, Johanna E. Gehin, David J. Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, Nils Bolstad, Espen A. Haavardsholm
Cite DOI
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that …
G. L. Goll, K. K. Jørgensen, J. Sexton, I. C. Olsen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, K. S. Tveit, M. Lorentzen, I. P. Berset, B. T. S. Fevang, S. Kalstad, K. Ryggen, D. J. Warren, R. A. Klaasen, Ø Asak, S. Baigh, I. M. Blomgren, Ø Brenna, T. J. Bruun, K. Dvergsnes, S. O. Frigstad, I. M. Hansen, I. S. H. Hatten, G. Huppertz-Hauss, M. Henriksen, S. S. Hoie, J. Krogh, I. P. Midtgard, P. Mielnik, B. Moum, G. Noraberg, A. Poyan, U. Prestegård, H. U. Rashid, E. K. Strand, K. Skjetne, K. A. Seeberg, R. Torp, C. M. Ystrøm, C. Vold, C. C. Zettel, K. Waksvik, B. Gulbrandsen, J. Hagfors, C. Mørk, J. Jahnsen, T. K. Kvien
Cite DOI
Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
OBJECTIVE: To describe the outcomes of MTX and biologic DMARD (bDMARD) treatment in patients with RA and assess unmet needs in patients …
Inge C. Olsen, Elisabeth Lie, Radu Vasilescu, Gene Wallenstein, Sander Strengholt, Tore K. Kvien
Cite DOI
Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases
OBJECTIVES: Patients with inflammatory joint diseases (IJD) have an increased risk of cardiovascular disease (CVD). Our goal was to …
Eirik Ikdahl, Grunde Wibetoe, Silvia Rollefstad, Anne Salberg, Kjetil Bergsmark, Tore K. Kvien, Inge C. Olsen, Dag Magnar Soldal, Gunnstein Bakland, Åse Lexberg, Bjørg Tilde Svanes Fevang, Hans Christian Gulseth, Glenn Haugeberg, Anne Grete Semb
Cite DOI
Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol
Objectives: To study prognostic factors for achievement of sustained remission in early RA patients receiving semi-personalized tight …
Nina Paulshus Sundlisæter, Inge C. Olsen, Anna-Birgitte Aga, Hilde B. Hammer, Till Uhlig, Désirée van der Heijde, Tore K. Kvien, Siri Lillegraven, Espen A. Haavardsholm, ARCTIC study group
Cite DOI
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes
OBJECTIVE: To explore associations between remission, based on clinical and ultrasound definitions, and future good radiographic and …
Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Désirée van der Heijde, Tore K. Kvien, Siri Lillegraven, Espen A. Haavardsholm, ARCTIC study group
Cite DOI
The Impact of Ultrasound on the Use and Efficacy of Intraarticular Glucocorticoid Injections in Early Rheumatoid Arthritis: Secondary Analyses From a Randomized Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regimen
OBJECTIVE: Intraarticular glucocorticoid injections are common in rheumatoid arthritis (RA) treatment. This study was undertaken to …
Lena B. Nordberg, Siri Lillegraven, Anna-Birgitte Aga, Joe Sexton, Elisabeth Lie, Hilde B. Hammer, Inge C. Olsen, Till Uhlig, Désirée van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Cite DOI
Discrepancies in risk age and relative risk estimations of cardiovascular disease in patients with inflammatory joint diseases
OBJECTIVE: The European guidelines on cardiovascular disease (CVD) prevention advise use of relative risk and risk age algorithms for …
Grunde Wibetoe, Eirik Ikdahl, Silvia Rollefstad, Inge C. Olsen, Kjetil Bergsmark, Tore K. Kvien, Anne Salberg, Dag M. Soldal, Gunnstein Bakland, Åse Lexberg, Bjørg-Tilde Fevang, Hans Christian Gulseth, Glenn Haugeberg, Anne Grete Semb
Cite DOI